Skip to content

Pharma and healthcare: sector news on Thursday 19 November 2026

Average tone +2.7 (slightly positive) across 5 companies with relevant coverage, from 36 stories.

How to read a score. Each score rates how good or bad the news was for the company, from −10 (clearly bad) to +10 (clearly good). 0 is neutral, and anything beyond ±6 is strong and rare. It rates the coverage, not the share price.

Company by company

CompanyToneStoriesWhat the coverage was about
AstraZeneca+5.523Coverage was mainly about the extended Tempus AI data agreement, US approval of a new Imfinzi bladder cancer regimen and a letter of intent between its Indian arm and Strand Life Sciences.
Haleon−1.75Coverage was mixed: shares fell after a lowered analyst target and a Zacks downgrade prompted valuation questions.
Convatec+10.04Coverage centred on Convatec lifting its revenue growth forecast, with shares jumping around 10%.
Smith & Nephew−2.03Coverage centred on a guidance cut that sent the shares lower and put the orthopaedics business under scrutiny.
GSK0.01

Strongest stories in the sector

Pharma and healthcare: every day · FTSE 100 overview for the day

Follow by email

A short, free morning email on how the news treated the Pharma and healthcare sector: the tone, the stories behind it, and when coverage starts to turn. Launching soon; one click to unsubscribe.

How it works. Every morning an AI model reads the UK business news about each FTSE 100 company and scores how good or bad it is for the company, from −10 to +10. Pages update by about 07:45 UK time.

Not investment advice. MarketFrame rates the tone of news coverage. It is general information, not a recommendation to buy or sell anything. The scores are not share-price data or forecasts: a good score doesn't mean a share will rise, and a bad one doesn't mean it will fall.

Data to 06:30 UTC, 19 November · 909 headlines · 82 companiesMade by Adapt Progress Evolve Limited, a UK company · Privacy · Terms · Who we are · RSS · API · llms.txt